1 |
Ain |
- |
- |
- |
- |
013 [1] 13 💬 |
2 |
Ain457 |
- |
- |
- |
- |
013 [7] 13, 37, 41, 46, 56, 96, 271 💬 |
3 |
Ain457, 150 mg |
- |
- |
- |
- |
271 [1] 271 💬 |
4 |
Ain457, 150mg |
- |
- |
- |
- |
037 [1] 37 💬 |
5 |
Ain457, 75 mg |
- |
- |
- |
- |
271 [1] 271 💬 |
6 |
Ain457a |
- |
- |
- |
- |
271 [1] 271 💬 |
7 |
Ain457f |
- |
- |
- |
- |
046 [2] 46, 271 💬 |
8 |
Humatrope 6 mg/12 mg/24 mg injektiokuiva-aine ja liuotin, liuosta varten |
- |
- |
- |
- |
193 [1] 193 💬 |
9 |
Remicade 100 mg infuusiokuiva-aine, konsentraattiliuosta varten |
- |
- |
- |
- |
097 [1] 97 💬 |
10 |
Secukinumab (ain457) |
Secukinumab |
[1] D09967 D09967 💬 |
IL17A [1] IL17A 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
046 [1] 46 💬 |
11 |
Secukinumab (ain457) 150 mg s.c. |
Secukinumab |
[1] D09967 D09967 💬 |
IL17A [1] IL17A 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
271 [1] 271 💬 |